Pdt Partners, LLC Sage Therapeutics, Inc. Transaction History

Pdt Partners, LLC

$1.28 Billion
Q1 2025

A detailed history of Pdt Partners, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 116,528 shares of SAGE stock, worth $1.08 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

116,528

Previous 235,097 50.43%

Holding current value

$1.08 Million

Previous $1.28 Million 27.43%

% of portfolio

0.07%

Previous 0.13%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$5.55 - $8.66 $658,057 - $1.03 Million	-118,569 Reduced 50.43%	116,528 $926,000
Q4 2024 Feb 14, 2025	BUY	$4.78 - $8.57 $304,983 - $546,800	63,804 Added 37.25%	235,097 $1.28 Million
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $437,689 - $815,524	-62,349 Reduced 26.69%	171,293 $1.24 Million
Q2 2024 Aug 15, 2024	BUY	$10.58 - $17.9 $954,866 - $1.62 Million	90,252 Added 62.94%	233,642 $2.54 Million
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $100,659 - $145,691	-5,406 Reduced 3.63%	143,390 $2.69 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $561,375 - $730,773	-32,829 Reduced 18.08%	148,796 $3.22 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $2.36 Million - $6.91 Million	141,094 Added 348.11%	181,625 $3.74 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $577,677 - $846,122	14,211 Added 53.99%	40,531 $1.91 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $615,290 - $768,824	16,509 Added 168.27%	26,320 $1.1 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $4,894 - $6,628	152 Added 1.57%	9,811 $374,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $2.44 Million - $3.27 Million	-75,502 Reduced 88.66%	9,659 $378,000
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $810,601 - $1.12 Million	-29,455 Reduced 25.7%	85,161 $2.75 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $1.13 Million - $1.69 Million	36,933 Added 47.54%	114,616 $3.79 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $415,702 - $528,432	-11,217 Reduced 12.62%	77,683 $3.31 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $133,220 - $189,837	-3,309 Reduced 3.59%	88,900 $3.94 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $2.56 Million - $3.7 Million	46,706 Added 102.64%	92,209 $5.24 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $1.93 Million - $2.64 Million	-27,297 Reduced 37.5%	45,503 $3.41 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $337,025 - $513,876	-5,770 Reduced 7.34%	72,800 $6.3 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $1.24 Million - $1.88 Million	-30,105 Reduced 27.7%	78,570 $4.8 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $2.82 Million - $4.69 Million	108,675 New	108,675 $4.52 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

50M

Call Options Held

220K

Put Options Held

312K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $553M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account